metformin has been researched along with Diarrhea in 38 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "BACKGROUND Metformin-associated lactic acidosis (MALA) is a relatively rare adverse effect of metformin therapy." | 8.12 | Transient Complete Blindness Due to Metformin-Associated Lactic Acidosis (MALA) Reversed with Hemodialysis. ( Barusya, C; Charokopos, A; Dumic, I; Knopps, L; Rueda Prada, L; Subramanian, A; Zurob, AS, 2022) |
| "Lactic acidosis is a rare, serious adverse effect of metformin, which can be prevented by carefully observing the contra-indications." | 6.41 | [Metformin efficacious in poorly controlled diabetes mellitus type 2]. ( Hoekstra, JB; Holleman, F; Stades, AM, 2000) |
| "Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the world." | 5.51 | Therapeutic effect of treatment with metformin and/or 4-hydroxychalcone in male Wistar rats with nonalcoholic fatty liver disease. ( Aguilar-Medina, EM; Centurión, D; de Jesús Acosta-Cota, S; Montes-Avila, J; Osuna-Martínez, U; Plazas-Guerrero, CG; Ramos-Payán, R; Rendón Maldonado, JG; Romero-Quintana, JG; Sánchez-López, A; Sarmiento-Sánchez, JI; Vergara-Jiménez, MJ, 2019) |
| "Metformin, first line medication in the treatment of type2 diabetes by millions of patients worldwide, causes gastrointestinal adverse effects (i." | 5.46 | "Metformin-resistant" folic acid producing probiotics or folic acid against metformin's adverse effects like diarrhea. ( Olgun, A, 2017) |
| "Patients with type 2 diabetes who are taking metformin and experience diarrhea deserve a drug-free interval before undergoing expensive and uncomfortable diagnostic tests, even when the dosage has been stable over a long period." | 5.31 | Metformin as a cause of late-onset chronic diarrhea. ( Clement, KD; Foss, MT, 2001) |
| "Compared with glimepiride, Sita/Met as an initial treatment led to significantly greater improvements in glycemic control and body weight changes, with a lower incidence of hypoglycemia, over 30 weeks." | 5.24 | Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study. ( Chung, SC; Kim, IJ; Kim, SS; Kim, YI; Lee, KJ; Lee, SJ; Lee, YS; Park, JH, 2017) |
| "Compared with metformin, vildagliptin combined with metformin could significantly reduce FPG, HbA1c and body weight." | 5.22 | Efficacy and safety of combination therapy with vildagliptin and metformin vs. metformin monotherapy for Type 2 Diabetes Mellitus therapy: a meta-analysis. ( Cao, L; Ding, Y; Dong, F; Li, Y; Lin, M; Lin, S; Liu, Y; Qu, Y, 2022) |
| "The risk of gastrointestinal adverse events such as abdominal pain, nausea and diarrhea is higher in type 2 diabetes patients treated with metformin compared to other antidiabetic drugs." | 5.22 | Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: A systematic review, meta-analysis and meta-regression of randomized controlled trials. ( Gumprecht, J; Hendel, M; Irlik, K; Januszkiewicz, K; Kwiendacz, H; Lip, GYH; Nabrdalik, K; Skonieczna-Żydecka, K; Łoniewski, I, 2022) |
| "Liraglutide provided better glycaemic control and greater body weight reduction than sitagliptin when administered as add-on to metformin." | 5.22 | Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial. ( Bian, F; Bosch-Traberg, H; Geng, J; Li, Y; Liu, J; Liu, Y; Luo, Y; Lv, X; Mu, Y; Peng, Y; Sun, Y; Yang, J; Zang, L, 2016) |
| " We performed a systematic analysis and compared the proportion of patients reporting nausea, vomiting or diarrhoea, for different doses and glucose-lowering background medications, and relative to a reference compound within the subclasses of short- (exenatide b." | 4.95 | Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. ( Abd El Aziz, MS; Bettge, K; Kahle, M; Meier, JJ; Nauck, MA, 2017) |
| "Digestive disorders (diarrhoea, vomiting) represent the most common metformin side-effects (around 30%) with this first-line drug treatment for type 2 diabetes." | 4.87 | Metformin and digestive disorders. ( Bouchoucha, M; Cohen, R; Uzzan, B, 2011) |
| "BACKGROUND Metformin-associated lactic acidosis (MALA) is a relatively rare adverse effect of metformin therapy." | 4.12 | Transient Complete Blindness Due to Metformin-Associated Lactic Acidosis (MALA) Reversed with Hemodialysis. ( Barusya, C; Charokopos, A; Dumic, I; Knopps, L; Rueda Prada, L; Subramanian, A; Zurob, AS, 2022) |
| "Nondiabetic patients with LAHNSCC were enrolled in the current study to receive escalating doses of metformin and CRT based on the modified toxicity probability interval design." | 2.94 | Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer. ( Desai, J; Desai, PB; Gulati, S; Gutkind, JS; Jandarov, R; Mierzwa, M; Molinolo, A; Morris, JC; Palackdharry, SM; Riaz, MK; Sadraei, NH; Takiar, V; Wise-Draper, TM; Zhu, Z, 2020) |
| " The mean terminal half-life (t1/2 ) was 2-3 h." | 2.82 | Safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-531, a first-in-class analogue of unacylated ghrelin, in healthy and overweight/obese subjects and subjects with type 2 diabetes. ( Abribat, T; Allas, S; Delale, T; Julien, M; Ngo, N; Ritter, J; Sahakian, P; van der Lely, AJ, 2016) |
| "Metformin XR was well tolerated; gastrointestinal side effects were more common with metformin XR vs." | 2.71 | Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-c ( Brazg, RL; Bruce, S; Fujioka, K; Joyal, S; Pans, M; Raz, I; Swanink, R, 2005) |
| " The overall results demonstrated that the use of oral antidiabetic agents (analysed separately and together) was not associated with any significantly increased risk of any serious adverse events including hypoglycaemia and gastrointestinal disorders." | 2.50 | The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. ( Kawalec, P; Mikrut, A; Łopuch, S, 2014) |
| "Lactic acidosis is a rare, serious adverse effect of metformin, which can be prevented by carefully observing the contra-indications." | 2.41 | [Metformin efficacious in poorly controlled diabetes mellitus type 2]. ( Hoekstra, JB; Holleman, F; Stades, AM, 2000) |
| "Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure with reduced ejection fraction." | 1.62 | Effect of Omecamtiv Mecarbil on the Pharmacokinetics of Metformin, a Probe Substrate for MATE1/MATE2-K, in Healthy Subjects. ( Abbasi, S; Dutta, S; Flach, S; Jafarinasabian, P; Lee, E; Oberoi, RK; Spring, M; Trivedi, A; Zhang, H, 2021) |
| "Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the world." | 1.51 | Therapeutic effect of treatment with metformin and/or 4-hydroxychalcone in male Wistar rats with nonalcoholic fatty liver disease. ( Aguilar-Medina, EM; Centurión, D; de Jesús Acosta-Cota, S; Montes-Avila, J; Osuna-Martínez, U; Plazas-Guerrero, CG; Ramos-Payán, R; Rendón Maldonado, JG; Romero-Quintana, JG; Sánchez-López, A; Sarmiento-Sánchez, JI; Vergara-Jiménez, MJ, 2019) |
| "Non-alcoholic fatty liver disease (NAFLD) may be associated with changes in bile acid (BA) metabolism." | 1.51 | Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study. ( Appleby, RN; Khan, S; Manousou, P; Moghul, I; Neal, TD; Walters, JRF; Yee, M, 2019) |
| "Metformin, first line medication in the treatment of type2 diabetes by millions of patients worldwide, causes gastrointestinal adverse effects (i." | 1.46 | "Metformin-resistant" folic acid producing probiotics or folic acid against metformin's adverse effects like diarrhea. ( Olgun, A, 2017) |
| "Data on risk factors for Clostridium difficile infection (CDI) in diabetic patients are scarce." | 1.42 | Predicting Clostridium difficile infection in diabetic patients and the effect of metformin therapy: a retrospective, case-control study. ( Barsheshet, A; Bishara, J; Eliakim-Raz, N; Fishman, G; Goldberg, E; Stein, GY; Yahav, D; Zvi, HB, 2015) |
| "Metformin is a drug to improve glycemic control by reducing insulin resistance and is currently considered to be one of the first-choice drugs for type 2 diabetes mellitus (T2DM)." | 1.38 | The evaluation of risk factors associated with adverse drug reactions by metformin in type 2 diabetes mellitus. ( Hori, A; Horikawa, Y; Itoh, Y; Kitaichi, K; Okayasu, S; Suwa, T; Takeda, J; Yamamoto, M, 2012) |
| "We report two cases who had symptomatic vitamin B12 deficiency related to metformin use; the mechanisms are discussed." | 1.33 | Metformin-related vitamin B12 deficiency. ( Dai, LK; Jean, W; Liu, KW, 2006) |
| "Patients with type 2 diabetes who are taking metformin and experience diarrhea deserve a drug-free interval before undergoing expensive and uncomfortable diagnostic tests, even when the dosage has been stable over a long period." | 1.31 | Metformin as a cause of late-onset chronic diarrhea. ( Clement, KD; Foss, MT, 2001) |
| "Chronic diarrhea was diagnosed in 32 patients (overall prevalence of 3." | 1.30 | The prevalence of chronic diarrhea among diabetic patients. ( Goldin, E; Israeli, E; Lysy, J, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.26) | 18.7374 |
| 1990's | 1 (2.63) | 18.2507 |
| 2000's | 7 (18.42) | 29.6817 |
| 2010's | 17 (44.74) | 24.3611 |
| 2020's | 11 (28.95) | 2.80 |
| Authors | Studies |
|---|---|
| Mehrpour, O | 1 |
| Saeedi, F | 1 |
| Hoyte, C | 1 |
| Hadianfar, A | 1 |
| Nakhaee, S | 1 |
| Brent, J | 1 |
| Rueda Prada, L | 1 |
| Knopps, L | 1 |
| Dumic, I | 1 |
| Barusya, C | 1 |
| Subramanian, A | 1 |
| Charokopos, A | 1 |
| Zurob, AS | 1 |
| Ding, Y | 1 |
| Liu, Y | 2 |
| Qu, Y | 1 |
| Lin, M | 1 |
| Dong, F | 1 |
| Li, Y | 2 |
| Cao, L | 1 |
| Lin, S | 1 |
| Nabrdalik, K | 2 |
| Skonieczna-Żydecka, K | 2 |
| Irlik, K | 1 |
| Hendel, M | 1 |
| Kwiendacz, H | 2 |
| Łoniewski, I | 2 |
| Januszkiewicz, K | 1 |
| Gumprecht, J | 2 |
| Lip, GYH | 1 |
| Mizoguchi, M | 1 |
| Takemori, H | 2 |
| Furukawa, S | 1 |
| Ito, M | 2 |
| Asai, M | 1 |
| Morino, H | 2 |
| Miura, T | 2 |
| Yabe, D | 1 |
| Shibata, T | 2 |
| Drożdż, K | 1 |
| Kaczmarczyk, M | 1 |
| Wijata, AM | 1 |
| Nalepa, J | 1 |
| Holleman, F | 2 |
| Nieuwdorp, M | 1 |
| de Jesús Acosta-Cota, S | 1 |
| Aguilar-Medina, EM | 1 |
| Ramos-Payán, R | 1 |
| Rendón Maldonado, JG | 1 |
| Romero-Quintana, JG | 1 |
| Montes-Avila, J | 1 |
| Sarmiento-Sánchez, JI | 1 |
| Plazas-Guerrero, CG | 1 |
| Vergara-Jiménez, MJ | 1 |
| Sánchez-López, A | 1 |
| Centurión, D | 1 |
| Osuna-Martínez, U | 1 |
| Gulati, S | 1 |
| Desai, J | 1 |
| Palackdharry, SM | 1 |
| Morris, JC | 1 |
| Zhu, Z | 1 |
| Jandarov, R | 1 |
| Riaz, MK | 1 |
| Takiar, V | 1 |
| Mierzwa, M | 1 |
| Gutkind, JS | 1 |
| Molinolo, A | 1 |
| Desai, PB | 1 |
| Sadraei, NH | 1 |
| Wise-Draper, TM | 1 |
| Hamamoto, A | 1 |
| Isogawa, K | 1 |
| Takagi, M | 1 |
| Oshida, K | 1 |
| Patoulias, D | 1 |
| Katsimardou, A | 1 |
| Kalogirou, MS | 1 |
| Zografou, I | 1 |
| Toumpourleka, M | 1 |
| Imprialos, K | 1 |
| Stavropoulos, K | 1 |
| Stergiou, I | 1 |
| Papadopoulos, C | 1 |
| Doumas, M | 1 |
| Yeku, OO | 1 |
| Medford, AJ | 1 |
| Fenves, AZ | 1 |
| Uljon, SN | 1 |
| Trivedi, A | 1 |
| Oberoi, RK | 1 |
| Jafarinasabian, P | 1 |
| Zhang, H | 1 |
| Spring, M | 1 |
| Flach, S | 1 |
| Abbasi, S | 1 |
| Dutta, S | 1 |
| Lee, E | 1 |
| Olgun, A | 1 |
| Appleby, RN | 1 |
| Moghul, I | 1 |
| Khan, S | 1 |
| Yee, M | 1 |
| Manousou, P | 1 |
| Neal, TD | 1 |
| Walters, JRF | 1 |
| Mendonça, FM | 1 |
| Leitão, MJ | 1 |
| Faria-Costa, G | 1 |
| Pires Da Rosa, G | 1 |
| Almeida, J | 1 |
| Wysham, C | 1 |
| Grimm, M | 1 |
| Chen, S | 1 |
| Kawalec, P | 1 |
| Mikrut, A | 1 |
| Łopuch, S | 1 |
| Eliakim-Raz, N | 1 |
| Fishman, G | 1 |
| Yahav, D | 1 |
| Goldberg, E | 1 |
| Stein, GY | 1 |
| Zvi, HB | 1 |
| Barsheshet, A | 1 |
| Bishara, J | 1 |
| Nunez, DJ | 1 |
| Yao, X | 1 |
| Lin, J | 1 |
| Walker, A | 1 |
| Zuo, P | 1 |
| Webster, L | 1 |
| Krug-Gourley, S | 1 |
| Zamek-Gliszczynski, MJ | 1 |
| Gillmor, DS | 1 |
| Johnson, SL | 1 |
| Zang, L | 1 |
| Geng, J | 1 |
| Luo, Y | 1 |
| Bian, F | 1 |
| Lv, X | 1 |
| Yang, J | 1 |
| Liu, J | 1 |
| Peng, Y | 1 |
| Sun, Y | 1 |
| Bosch-Traberg, H | 1 |
| Mu, Y | 1 |
| Allas, S | 1 |
| Delale, T | 1 |
| Ngo, N | 1 |
| Julien, M | 1 |
| Sahakian, P | 1 |
| Ritter, J | 1 |
| Abribat, T | 1 |
| van der Lely, AJ | 1 |
| Kim, SS | 1 |
| Kim, IJ | 1 |
| Lee, KJ | 1 |
| Park, JH | 1 |
| Kim, YI | 1 |
| Lee, YS | 1 |
| Chung, SC | 1 |
| Lee, SJ | 1 |
| Bettge, K | 1 |
| Kahle, M | 1 |
| Abd El Aziz, MS | 1 |
| Meier, JJ | 1 |
| Nauck, MA | 1 |
| Soudet, S | 1 |
| Lambert, M | 1 |
| Lefèvre, G | 1 |
| Maillard, H | 1 |
| Huglo, D | 1 |
| Hatron, PY | 1 |
| Gould, M | 1 |
| Sellin, JH | 1 |
| Li, XJ | 1 |
| Yu, YX | 1 |
| Liu, CQ | 1 |
| Zhang, W | 1 |
| Zhang, HJ | 1 |
| Yan, B | 1 |
| Wang, LY | 1 |
| Yang, SY | 1 |
| Zhang, SH | 1 |
| Bouchoucha, M | 1 |
| Uzzan, B | 1 |
| Cohen, R | 1 |
| Yang, W | 1 |
| Guan, Y | 1 |
| Shentu, Y | 1 |
| Li, Z | 1 |
| Johnson-Levonas, AO | 1 |
| Engel, SS | 1 |
| Kaufman, KD | 1 |
| Goldstein, BJ | 1 |
| Alba, M | 1 |
| Okayasu, S | 1 |
| Kitaichi, K | 1 |
| Hori, A | 1 |
| Suwa, T | 1 |
| Horikawa, Y | 1 |
| Yamamoto, M | 1 |
| Takeda, J | 1 |
| Itoh, Y | 1 |
| Fujioka, K | 1 |
| Brazg, RL | 1 |
| Raz, I | 1 |
| Bruce, S | 1 |
| Joyal, S | 1 |
| Swanink, R | 1 |
| Pans, M | 1 |
| Liu, KW | 1 |
| Dai, LK | 1 |
| Jean, W | 1 |
| Geberhiwot, T | 1 |
| Jones, AF | 1 |
| Lysy, J | 1 |
| Israeli, E | 1 |
| Goldin, E | 1 |
| Raju, B | 1 |
| Resta, C | 1 |
| Tibaldi, JT | 1 |
| Stades, AM | 1 |
| Hoekstra, JB | 1 |
| Foss, MT | 1 |
| Clement, KD | 1 |
| Lim, P | 1 |
| Khoo, OT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes.(LIRA-DPP-4 CHINA™)[NCT02008682] | Phase 4 | 368 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
| A Multicenter, Randomized, Double Blind Study to Compare the Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (Janumet®) Compared to Glimepiride in Patients With Type 2 Diabetes Mellitus[NCT00993187] | Phase 4 | 292 participants (Actual) | Interventional | 2010-05-04 | Completed | ||
| A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin 100 mg Once Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Monotherapy[NCT00813995] | Phase 3 | 395 participants (Actual) | Interventional | 2008-12-09 | Completed | ||
| The Benefits of Vitamin B Combination as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient: Randomized Clinical Trial[NCT04689971] | Phase 2/Phase 3 | 60 participants (Anticipated) | Interventional | 2020-11-03 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mean change from baseline in mean of 7-point self-measured plasma glucose at week 26. The 7-point self-measured plasma glucose levels were measured before and after (120 minutes after the start of the meal) the three main meals (breakfast, lunch and dinner), and at bed time. (NCT02008682)
Timeframe: Week 0, week 26
| Intervention | mmol/L (Mean) |
|---|---|
| Liraglutide | -2.25 |
| Sitagliptin | -1.36 |
Mean change from baseline in fasting plasma glucose (FPG) at Week 26. (NCT02008682)
Timeframe: Week 0, week 26
| Intervention | mmol/L (Mean) |
|---|---|
| Liraglutide | -2.347 |
| Sitagliptin | -1.205 |
Mean change from baseline in glycosylated haemoglobin A1c (HbA1c) at Week 26. (NCT02008682)
Timeframe: Week 0, week 26
| Intervention | Percent (%) glycosylated haemoglobin (Mean) |
|---|---|
| Liraglutide | -1.666 |
| Sitagliptin | -0.969 |
confirmed hypoglycaemic episode defined as severe (unable to treat her/himself) or biochemically confirmed by a plasma glucose < 3.1 mmol/L (NCT02008682)
Timeframe: Weeks 0-26
| Intervention | episodes (Number) |
|---|---|
| Liraglutide | 2 |
| Sitagliptin | 1 |
Calculated as the percentage of subjects achieving treatment target of HbA1c < 7.0% at Week 26 (NCT02008682)
Timeframe: After 26 weeks of treatment
| Intervention | percentage of subjects (Number) |
|---|---|
| Liraglutide | 76.5 |
| Sitagliptin | 52.6 |
Calculated as the percentage of subjects achieving treatment target of HbA1c <= 6.5% at Week 26 (NCT02008682)
Timeframe: After 26 weeks of treatment
| Intervention | percentage of subjects (Number) |
|---|---|
| Liraglutide | 61.7 |
| Sitagliptin | 26.3 |
Change in body weight following 30 weeks of therapy (i.e., body weight at Week 30 minus body weight at baseline) (NCT00993187)
Timeframe: Baseline and Week 30
| Intervention | kg (Least Squares Mean) |
|---|---|
| Sitagliptin/Metformin | -0.83 |
| Glimepiride | 0.90 |
Blood glucose was measured on a fasting basis (collected after an 8- to 10-hour fast). FPG is expressed as mg/dL. Blood was drawn at predose on Day 1 and after 30 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 30 minus FPG at baseline). (NCT00993187)
Timeframe: Baseline and Week 30
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Sitagliptin/Metformin | -47.0 |
| Glimepiride | -23.5 |
HbA1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). Change in A1C following 30 weeks of therapy (i.e., A1C at Week 30 minus A1C at baseline). (NCT00993187)
Timeframe: Baseline and Week 30
| Intervention | Percent of total hemoglobin (Least Squares Mean) |
|---|---|
| Sitagliptin/Metformin | -1.5 |
| Glimepiride | -0.7 |
An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product. (NCT00993187)
Timeframe: Up to 30 weeks
| Intervention | Participants (Number) |
|---|---|
| Sitagliptin/Metformin | 8 |
| Glimepiride | 8 |
An adverse event (AE) is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product. (NCT00993187)
Timeframe: Up to 32 weeks
| Intervention | Participants (Number) |
|---|---|
| Sitagliptin/Metformin | 88 |
| Glimepiride | 101 |
HbA1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). (NCT00993187)
Timeframe: Week 30
| Intervention | Percentage of Participants (Number) |
|---|---|
| Sitagliptin/Metformin | 81.2 |
| Glimepiride | 40.1 |
Symptomatic episodes assessed as likely to be due to hypoglycemia were reported by investigators as adverse experiences of hypoglycemia. Adverse experiences of hypoglycemia were based on all reports of hypoglycemia; a concurrent glucose measurement was not required. (NCT00993187)
Timeframe: Up to Week 30
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin/Metformin | 5.5 |
| Glimepiride | 20.1 |
Change from baseline at Week 24 is defined as Week 24 minus Week 0. (NCT00813995)
Timeframe: Baseline and Week 24
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Sitagliptin | -43.4 |
| Placebo | -10.0 |
Change from baseline at Week 24 is defined as Week 24 minus Week 0. (NCT00813995)
Timeframe: Baseline and Week 24
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Sitagliptin | -20.3 |
| Placebo | 0.5 |
A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent. (NCT00813995)
Timeframe: Baseline and Week 24
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Sitagliptin | -1.02 |
| Placebo | -0.14 |
A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent. (NCT00813995)
Timeframe: Baseline and Week 24
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Sitagliptin | -0.84 |
| Placebo | -0.01 |
A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent. (NCT00813995)
Timeframe: Baseline and Week 24
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Sitagliptin | -1.14 |
| Placebo | -0.21 |
9 reviews available for metformin and Diarrhea
| Article | Year |
|---|---|
Efficacy and safety of combination therapy with vildagliptin and metformin vs. metformin monotherapy for Type 2 Diabetes Mellitus therapy: a meta-analysis.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diarrhea; Dizziness; Drug Therapy, Combinatio | 2022 |
Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: A systematic review, meta-analysis and meta-regression of randomized controlled trials.
Topics: Abdominal Pain; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diarrhea; Humans; Hypoglycem | 2022 |
Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diarrhea; Drug Therapy, Combination; Glucagon-Like Peptide | 2020 |
Once weekly exenatide: efficacy, tolerability and place in therapy.
Topics: Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diarrhea; Drug Administration | 2013 |
The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Diarrhea; Dipeptidyl-Peptidase IV Inhibitors; Drug | 2014 |
Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diarrhea; Drug Therapy, Combination; Exenatide; | 2017 |
Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis.
Topics: Dehydroepiandrosterone Sulfate; Diarrhea; Female; Humans; Hypoglycemic Agents; Metformin; Nausea; Pi | 2011 |
Metformin and digestive disorders.
Topics: Bile Acids and Salts; Diabetes Mellitus, Type 2; Diarrhea; Digestive System Diseases; Glucose; Human | 2011 |
[Metformin efficacious in poorly controlled diabetes mellitus type 2].
Topics: Abdominal Pain; Acidosis, Lactic; Aged; Blood Glucose; Contraindications; Diabetes Mellitus; Diabete | 2000 |
8 trials available for metformin and Diarrhea
21 other studies available for metformin and Diarrhea
| Article | Year |
|---|---|
Distinguishing characteristics of exposure to biguanide and sulfonylurea anti-diabetic medications in the United States.
Topics: Abdominal Pain; Acidosis; Adolescent; Adult; Aged; Child; Creatinine; Diabetes Mellitus; Diarrhea; D | 2022 |
Transient Complete Blindness Due to Metformin-Associated Lactic Acidosis (MALA) Reversed with Hemodialysis.
Topics: Acidosis, Lactic; Acute Kidney Injury; Aged; Blindness; Diabetes Mellitus, Type 2; Diarrhea; Female; | 2022 |
Increased expression of glucagon-like peptide-1 and cystic fibrosis transmembrane conductance regulator in the ileum and colon in mouse treated with metformin.
Topics: Animals; Caco-2 Cells; Colon; Creosote; Cyclic AMP; Cystic Fibrosis Transmembrane Conductance Regula | 2023 |
Therapeutic effect of treatment with metformin and/or 4-hydroxychalcone in male Wistar rats with nonalcoholic fatty liver disease.
Topics: Animals; Chalcones; Collagen; Cytokines; Diarrhea; Drug Interactions; Eating; Liver; Male; Metformin | 2019 |
Mouse model of metformin-induced diarrhea.
Topics: Animals; Diabetes Mellitus, Type 2; Diarrhea; Humans; Hypoglycemic Agents; Metformin; Mice; Mice, In | 2020 |
Case 15-2021: A 76-Year-Old Woman with Nausea, Diarrhea, and Acute Kidney Failure.
Topics: Acidosis, Lactic; Acute Kidney Injury; Aged; Coronary Artery Disease; Creatinine; Diabetes Mellitus, | 2021 |
Effect of Omecamtiv Mecarbil on the Pharmacokinetics of Metformin, a Probe Substrate for MATE1/MATE2-K, in Healthy Subjects.
Topics: Administration, Oral; Adult; Area Under Curve; Diarrhea; Drug Interactions; Female; Half-Life; Healt | 2021 |
"Metformin-resistant" folic acid producing probiotics or folic acid against metformin's adverse effects like diarrhea.
Topics: Animals; Diabetes Mellitus, Type 2; Diarrhea; Directed Molecular Evolution; Folic Acid; Gastrointest | 2017 |
Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Bile Acids and Salts; Cholestenones; Diarrhea; | 2019 |
Chronic diarrhea: an unusual clinical presentation of vitamin B
Topics: Diabetes Mellitus, Type 1; Diarrhea; Humans; Male; Metformin; Middle Aged; Vitamin B 12; Vitamin B 1 | 2019 |
Predicting Clostridium difficile infection in diabetic patients and the effect of metformin therapy: a retrospective, case-control study.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Clostridioides difficile; Clostridium Infectio | 2015 |
Long term use of metformin in idiopathic cyclic edema, report of thirteen cases and review of the literature.
Topics: Adult; Aged; Capillary Permeability; Diarrhea; Edema; Female; Humans; Hypoglycemic Agents; Male; Met | 2017 |
Diabetic diarrhea.
Topics: Algorithms; Antidiarrheals; Celiac Disease; Clonidine; Colitis; Diabetes Complications; Diabetes Mel | 2009 |
The evaluation of risk factors associated with adverse drug reactions by metformin in type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Alkaline Phosphatase; Asian People | 2012 |
Metformin-related vitamin B12 deficiency.
Topics: Aged, 80 and over; Diabetes Mellitus, Type 2; Diarrhea; Female; Humans; Hypoglycemic Agents; Metform | 2006 |
Treatment of infertility in the polycystic ovary syndrome.
Topics: Clomiphene; Diarrhea; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; Hypoglyce | 2007 |
Diabetes and bowel habits.
Topics: Anal Canal; Diabetes Complications; Diabetes Mellitus; Diarrhea; Fecal Incontinence; Humans; Metform | 1983 |
The prevalence of chronic diarrhea among diabetic patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care Facilities; Autonomic Nervous System Dis | 1999 |
Metformin and late gastrointestinal complications.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Diarrhea; Drug Administration Schedule; Female; Humans; Hypo | 2000 |
Metformin as a cause of late-onset chronic diarrhea.
Topics: Chronic Disease; Diabetes Mellitus, Type 2; Diarrhea; Female; Humans; Hypoglycemic Agents; Metformin | 2001 |
Metformin compared with tolbutamide in the treatment of maturity-onset diabetes mellitus.
Topics: Adult; Diabetes Mellitus; Diarrhea; Female; Humans; Hyperglycemia; Male; Metformin; Middle Aged; Tol | 1970 |